<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00493077</url>
  </required_header>
  <id_info>
    <org_study_id>SAFE</org_study_id>
    <nct_id>NCT00493077</nct_id>
  </id_info>
  <brief_title>Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy</brief_title>
  <acronym>SAFE</acronym>
  <official_title>A Swedish Multi-Centre, Prospective, Open Label Study: Safety of Avonex Treatment in Multiple Sclerosis Patients Who Are NAB Positive on Previous s.c Interferon Beta Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to find out the safety and effectiveness of Avonex (interferon-beta-1a) Therapy
      in patients who have developed neutralizing antibodies during previous interferon-beta
      treatment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-centre, prospective, open label, non-comparative phase IV trial. Eligible
      patients will receive treatment with IFN-beta-1a AVONEX® 30 mcg i.m. once weekly for 12
      months.The patients will be examined clinically and NAb titres will be performed at screening
      and after 12 months. Adverse event source verification will be performed during the
      documentation period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>neutralizing antibody levels will be followed</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with NAb positive titre &gt; 20.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change from baseline (screening) of NAb titre</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the annualised relapse rate and number of relapse-free (total and documented relapses) patients</measure>
    <time_frame>12 months and as needed for relapses</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients with a loss of disability of 1.0 (or more) score on the EDSS.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low immunogenic interferon-beta-1a</intervention_name>
    <description>dosage and frequency as per Biogen Idec protocol</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Avonex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsing-remitting MS according to Poser criteria(CDMS or LSDMS)30 or MS according to
             McDonald criteria

          -  Disability equivalent to an EDSS of 6.0 or less at screening

          -  Neutralizing antibody titre &gt; 20 and &lt;500 in two consecutive NAb tests. One must be
             from before screening

          -  previous treatment with either subcutaneous administered interferon-b-1b (Betaferon®)
             or interferon-b-1a (Rebif TM) prior to enrolment

          -  A priori has been decided to be treated with AVONEX

        Exclusion Criteria:

          -  Is NAb positive on AVONEX

          -  History of major depression

          -  Cardiac insufficiency, cardiomyopathy, significant cardiac dysrhythmia, unstable or
             advanced ischemic heart disease (NYHA III or IV), or significant hypertension (BP &gt;
             180/110 mmHg)

          -  Renal insufficiency defined as serum creatinine &gt; 1.5 times the upper normal reference
             limit

          -  Any systemic disease that can influence the patient's safety and compliance, or the
             evaluation of the disability

          -  Women who are pregnant, breast-feeding or have the possibility for pregnancy during
             the trial. To avoid pregnancy, women have to be postmenopausal, surgical sterile,
             sexually inactive or practice reliable contraceptives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Biogen-Idec Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>neurologyclinicaltrials@biogenidec.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goteborg</city>
        <zip>416 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coordinating Research Site</name>
      <address>
        <city>Huddinge</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Joenkoeping</city>
        <zip>551 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Karlstad</city>
        <zip>651 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2007</study_first_submitted>
  <study_first_submitted_qc>June 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2007</study_first_posted>
  <last_update_submitted>January 28, 2008</last_update_submitted>
  <last_update_submitted_qc>January 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2008</last_update_posted>
  <responsible_party>
    <name_title>biogen Idec MD</name_title>
    <organization>Biogen Idec</organization>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Neutralizing antibodies</keyword>
  <keyword>Safety</keyword>
  <keyword>Low immunogenicity</keyword>
  <keyword>interferon</keyword>
  <keyword>interferon-beta-1a</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1a</mesh_term>
    <mesh_term>Antibodies, Blocking</mesh_term>
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

